The Swiss cannabis pilot projects

TL;DR

• Basis: NarcA Art. 8a (in force since 15.5.2021).
• Active trials: Basel (2023), Zurich (2023), Bern (2024), Lausanne (2024), Geneva (2024), Lucerne (2025).
• Duration: up to 5 years per trial.
• Participation limited to adult residents of the respective city.

How the pilot projects work

• Registration with ID + proof of consumption (urine THC test).
• Pickup at selected pharmacies or social clubs.
• Prices: aligned with black-market level (~CHF 10/g).
• Scientific evaluation by universities (Basel: Uni Basel; Zurich: PUK).
• Results feed the legalization debate 2026–28.

What the pilot trials actually mean commercially – and what they don't

Pilot trials under Art. 8a NarcA are scientific studies, not market liberalisation. Participants are recruited, registered and monitored; quantities, product range and prices are fixed. For companies this creates no open sales channel but a narrowly defined supply mandate: suppliers must demonstrate GACP- or GMP-adjacent production standards, batch analytics and traceability, and contract with the study sponsor rather than end customers.

The trials still matter commercially – as groundwork, not revenue. They generate the first solid Swiss dataset on price elasticity, product preferences (flower vs. extracts vs. edibles) and black-market substitution. Those data will shape the parameters of any later regulatory model. Firms involved today as producers, analytical labs or seed-to-sale software vendors mainly gain references, process maturity and regulatory relationships.

• Pilot trial = study with a fixed participant pool, not open sales.
• Supply contracts run through the study sponsor (city/university), not end customers.
• Requirements: batch analytics, traceability, defined THC/CBD levels, packaging rules.
• The real value for firms lies in references and process maturity for a later regime.

The legal framework and the role of the Federal Office of Public Health

The legal basis for conducting the scientific pilot trials is based on the revised Narcotics Act. The Federal Office of Public Health (BAG) reviews and approves each individual project in close cooperation with the cantonal authorities and scientific institutes. These trials are strictly regulated, limited in time, and primarily serve to investigate the effects of regulated access on the health of consumers and on the black market. The general status of cannabis with a total THC content of over one percent as a prohibited substance in the rest of the country remains unaffected.

While medical cannabis has been allowed to be prescribed directly by treating physicians without an exceptional licence from the FOPH since August 2022, the pilot projects are aimed exclusively at recreational consumers. Official supervision ensures that distribution is controlled and that youth protection and prevention are paramount. The findings from these projects, which are limited to specific cantons, are ultimately intended to serve as a sound basis for decision-making by the legislator for future national regulation.

• Responsibility and granting of licences by the Federal Office of Public Health (FOPH).
• Strict separation between medical prescription and scientific pilot trials.
• Strictly time-limited and geographically restricted exceptional licences in accordance with the Narcotics Act (BetmG).
• Focus on youth protection, harm reduction, and accompanying scientific research.

Road traffic and the zero-tolerance policy for participants

A critical aspect for all participants in the Swiss pilot trials is the legal situation in road traffic. Even though the acquisition and consumption within the framework of the scientific studies are tolerated and legalised by the state, this does not exempt anyone from the strict rules of the Road Traffic Act. In Switzerland, a strict zero-tolerance policy applies to driving under the influence of tetrahydrocannabinol. Anyone caught at the wheel with active substances in their blood must expect drastic criminal and administrative consequences.

The legally established limit is 1.5 micrograms of THC per litre of blood serum. Since this value can still be exceeded hours or even days after the last consumption, study participants face a significant risk of driving licence revocation. Confirmation of participation in a pilot project does not protect against criminal prosecution for unfitness to drive. Anyone participating in the trials who relies on their driving licence must therefore plan their consumption and mobility with extreme precision and responsibility.

• Unchanged validity of the zero-tolerance limit of 1.5 µg/L THC in blood serum.
• No special legal status or protection against driving licence revocation through study participation.
• Risk of detectability in the blood long after the actual state of intoxication has subsided.
• Necessity of a strict separation between consumption and participation in road traffic.

Quality requirements and product safety in cultivation

The products dispensed within the framework of the pilot projects must meet the highest quality standards, which clearly set them apart from the unregulated black market. The agricultural enterprises cultivating for the studies must adhere to strict guidelines of good practice for the collection and cultivation of medicinal plants. This guarantees that the flowers are free from pesticides, heavy metals, moulds, or other contaminants hazardous to health. Each batch is analysed and certified in specialised laboratories before sale.

Furthermore, the addition of synthetic cannabinoids, which represent a growing health risk on the illegal market, is strictly prohibited. The Federal Food Safety and Veterinary Office (BLV) and Swissmedic set strict standards for product safety in this regard. Through the transparent declaration of the exact THC and CBD content, consumers gain precise control over the potency of the products. This enables lower-risk consumption and protects against unexpectedly strong psychoactive effects.

• Mandatory cultivation according to strict guidelines to ensure freedom from contaminants.
• Detailed laboratory analyses of each batch regarding active ingredient content and purity.
• Prohibition of synthetic cutting agents and artificial cannabinoids.
• Transparent declaration of all ingredients directly on the product packaging.

Federalism and cantonal differences in enforcement

Although the BetmG / Narcotics Act applies at the federal level, Swiss federalism shows its classic side in its enforcement. The cantons and municipalities possess considerable leeway in the design and monitoring of the pilot trials. While some cities such as Basel and Zurich rely heavily on dispensing via established pharmacies, other regions are testing alternative models such as cooperatively organised social clubs. These different approaches are intended to show which dispensing structure offers the best social control and guidance in practice.

Even outside the pilot projects, police practice differs noticeably from canton to canton. Although federal law provides for a fixed penalty fine of one hundred Swiss francs for adults in possession of up to ten grams of THC cannabis for personal consumption, the tolerance limits and control intensities of local security authorities vary widely. For the scientific evaluation of the pilot trials, however, this cantonal diversity is an advantage, as different social framework conditions can be directly compared with one another.

• Cantonal differences in dispensing points between pharmacies and social clubs.
• Federalistic handling of controls and the enforcement of fixed penalty fines.
• Comparability of different societal and structural models through the studies.
• Regional accompanying measures for prevention and education of the local population.

FAQ